Summary: Researchers have uncovered a powerful brain-to-body pathway that triggers rapid loss of all body fat — including biologically “stubborn” fat — without requiring any reduction in food intake. This discovery, led by a team at WashU Medicine, describes how a central leptin signal puts the body into a low-glucose, low-insulin state that disables protective proteins in certain fat cells and allows widespread fat breakdown.
Inspired by fat cells in bone marrow that typically resist change through diet or exercise, the investigators found that delivering leptin directly to the brain unlocks these stable adipocytes. The resulting metabolic state strips away inhibitors of lipolysis, producing near-complete loss of adipose tissue in experimental animals within days, even while normal eating continues.
This mechanism suggests new directions for obesity treatment by targeting otherwise resistant fat stores, but it also raises important clinical concerns. Stable adipocytes support bone health and glandular function; loss of these fat pads in wasting disorders contributes to bone fragility and fractures. The research therefore provides a dual roadmap: how to prevent catastrophic fat loss in patients with cachexia and how to safely harness the pathway for obesity therapies.
Key Facts
- Leptin as the central trigger: Prolonged leptin signaling in the brain acts as a master switch that initiates fat breakdown across the body, including from otherwise resistant depots.
- Targeting stable fat depots: The study highlights constitutive bone marrow adipocytes — fat cells found in the skeleton and in extremities like the hands and feet — which are normally resistant to day-to-day lipolytic cues.
- Insulin and glucose suppression: The pathway operates by producing hypoglycaemia and hypoinsulinaemia, which reduce cell-autonomous inhibitors of lipolysis and permit widespread adipose catabolism.
- Clinical implications are two-sided: While activating this pathway could aid obesity treatment, unregulated loss of stable adipocytes in wasting diseases is linked to bone fractures and poorer quality of life, so caution and targeted approaches are essential.
- Fat loss without reduced intake: In the animal model, total-body adipose depletion occurred rapidly while animals continued normal food consumption.
Source: WUSTL
Overview of the study
Researchers at Washington University School of Medicine (WashU Medicine) report these findings in Nature Metabolism. The team was led by Erica L. Scheller, DDS, PhD, with contributions from Xiao Zhang, PhD, and Sree Panicker, among others. Their work focused on a distinct population of fat cells embedded in bone marrow that make up a substantial portion of marrow content and are traditionally resistant to weight loss from diet or exercise.
The researchers named these cells “stable adipocytes” because of their resistance to typical lipolytic signals. They discovered that the cells express high levels of proteins that actively inhibit lipid breakdown. By delivering leptin centrally to the brain in mice, the investigators created a metabolic profile of low blood glucose and low insulin that suppressed those inhibitory proteins and allowed adipose triglyceride lipase–dependent lipolysis to proceed. The result was widespread delipidation of fat stores, including these stable depots, within a matter of days.
Because the pathway bypasses local sympathetic activation and catecholamine signaling, the authors describe it as a catecholamine-independent neurosystemic mechanism for controlling adaptive adipocyte lipolysis. The investigators emphasize that this system appears to be a powerful neural override capable of mobilizing otherwise protected energy reserves.
Key questions answered
Q: Does this mean fat can be lost without eating less?
A: In the experimental model, yes. Activating a specific central leptin signal produced a metabolic state that caused the body to catabolize fat stores, including stable adipocytes, while food intake remained unchanged.
Q: How is bone marrow fat different from visceral or subcutaneous fat?
A: Bone marrow and other stable fat depots serve structural and protective roles and are biologically programmed to resist routine lipolysis. This study identifies a neural mechanism that can override that resistance under specific metabolic conditions.
Q: Is this a ready-to-use weight-loss therapy for humans?
A: Not yet. The pathway is potent and not fully understood in humans. Because stable adipocytes support skeletal integrity, research is currently focused on preventing harmful fat loss in wasting illnesses while investigating whether selective, safe activation could help treat obesity in the future.
Editorial notes
- This article was edited by a Neuroscience News editor.
- The underlying journal paper was reviewed in full by editorial staff.
- Additional context was added for clarity.
About this weight loss and neuroscience research
Author: Jaci McDonald
Source: WUSTL
Contact: Jaci McDonald – WUSTL
Image: Image credited to Neuroscience News
Original research (open access): “A catecholamine-independent pathway controlling adaptive adipocyte lipolysis” by Xiao Zhang, Sreejith S. Panicker, Jordan M. Bollinger, Anurag Majumdar, Rami Kheireddine, Lila F. Dabill, Clara Kim, Brian Kleiboeker, Fengrui Zhang, Yongbin Chen, Kristann L. Magee, Brian S. Learman, Adam Kepecs, Gretchen A. Meyer, Jun Liu, Steven A. Thomas, Irfan J. Lodhi, Ormond A. MacDougald, and Erica L. Scheller. Nature Metabolism. DOI: 10.1038/s42255-025-01424-5
Abstract (concise)
Certain adipose depots, especially constitutive bone marrow adipose tissue, resist common lipolytic signals. Under conditions such as starvation, cachexia, or experimental central leptin signaling, the body can nevertheless catabolize these stable adipocytes through a pathway that does not require catecholamines. Using genetic, surgical and pharmacologic approaches in mice, the authors show that adipose triglyceride lipase–dependent lipolysis drives this process, and that concurrent hypoglycaemia and hypoinsulinaemia downregulate cell-intrinsic inhibitors of lipolysis (including G0s2). This catecholamine-independent neurosystemic pathway rapidly mobilizes lipids from both stable and classical adipose depots, defining an adaptive mechanism that protects energy stores in healthy conditions but can be engaged to deplete adipose tissue in wasting states or, potentially, targeted for obesity treatment.